In 2012, the cardiac ablation catheter market was valued at $307.1 million, an increase over the previous year.
What’s driving this market? Unit and procedural growth will be the main driver. Over the forecast period,
the popularization of more expensive catheter models is expected to mitigate the effects of competitive
pricing. For example, in 2008, Biosense Webster was able to keep prices high for their ThermoCool®
product, the only device approved for A-Fib catheter ablation. This device was approved in 2008 and
caused a slight spike in the market growth curve.
As for the number of units sold; they are expected to grow more rapidly after official FDA approval of minimally invasive A-Fib treatments.